Josep Merlo-Mas

Josep Merlo-Mas

Auto-generated profile, based on publicly available information

Josep Merlo-Mas

Nanomol Technologies SL, Campus de la UAB, 08193 Bellaterra, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2021 in Small
Verified
Journal Article
Open access
PDF file
ABAriadna Boloix
Ariadna Boloix
NFNatalia Feiner‐Gracia
Natalia Feiner‐Gracia
Mariana KöberMariana Köber
Mariana Köber
JRJavier Repetto
Javier Repetto
RPRosa Pascarella
Rosa Pascarella
Nora VentosaNora Ventosa
Nora Ventosa
MicroRNAs (miRNAs) are small non‐coding endogenous RNAs, which are attracting a growing interest as therapeutic molecules due to their central role in major diseases. However, the transformation of these biomolecules into drugs is limited due to their unstability in the bloodstream, caused by nucleases abundantly present in the blood, and poor capacity to enter cells. The conjugation of miRNAs to nanoparticles (NPs) could be an effective strategy for their clinical delivery. Herein, the engineering of non‐liposomal lipid nanovesicles, named quatsomes (QS), for the delivery of miRNAs and other small RNAs into the cytosol of tumor cells, triggering a tumor‐suppressive response is reported. The engineered pH‐sensitive nanovesicles have controlled structure (unilamellar), size (24 weeks), and are prepared by a green, GMP compliant, and scalable one‐step procedure, which are all unavoidable requirements for the arrival to the clinical practice of NP based miRNA therapeutics. Furthermore, QS protect miRNAs from RNAses and when injected intravenously, deliver them into liver, lung, and neuroblastoma xenografts tumors. These stable nanovesicles with tunable pH sensitiveness constitute an attractive platform for the efficient delivery of miRNAs and other small RNAs with therapeutic activity and their exploitation in the clinics.

14 February 2021 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
JTJudit Tomsen-Melero
Judit Tomsen-Melero
SPSolène Passemard
Solène Passemard
NGNatalia García-Aranda
Natalia García-Aranda
ZDZamira Vanessa Díaz-Riascos
Zamira Vanessa Díaz-Riascos
RGRamon González-Rioja
Ramon González-Rioja
Nora VentosaNora Ventosa
Nora Ventosa

13 December 2024 in Science Advances
Verified
Journal Article
Open access
JTJudit Tomsen-Melero
Judit Tomsen-Melero
MMMarc Moltó-Abad
Marc Moltó-Abad
JMJosep Merlo-Mas
Josep Merlo-Mas
ZDZamira V. Díaz-Riascos
Zamira V. Díaz-Riascos
ECEdgar Cristóbal-Lecina
Edgar Cristóbal-Lecina
EGElisabet González-Mira
Elisabet González-Mira
The central nervous system represents a major target tissue for therapeutic approach of numerous lysosomal storage disorders. Fabry disease arises from the lack or dysfunction of the lysosomal alpha-galactosidase A (GLA) enzyme, resulting in substrate accumulation and multisystemic clinical manifestations. Current enzyme replacement therapies (ERTs) face limited effectiveness due to poor enzyme biodistribution in target tissues and inability to reach the brain. We present an innovative drug delivery strategy centered on a peptide-targeted nanoliposomal formulation, designated as nanoGLA, engineered to selectively deliver a recombinant human GLA (rhGLA) to target tissues. In a Fabry mouse model, nanoGLA demonstrated improved efficacy, inducing a notable reduction in Gb3 deposits in contrast to non-nanoformulated GLA, even in the brain, highlighting the potential of the nanoGLA to address both systemic and cerebrovascular manifestations of Fabry disease. The EMA has granted the Orphan Drug Designation to this product, underscoring the potential clinical superiority of nanoGLA over authorized ERTs and encouraging to advance it toward clinical translation.